secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-05-20T12:00:35+00:00
Accession:  0001493152-26-024517
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharma reports peer-reviewed Telomir-Zn data showing survival benefit in Wilson's disease model
--------------------------------------------------------------------------------

- Telomir-Zn dose-dependently improved survival, reduced hepatic copper burden and liver injury biomarkers (ALT, AST, bilirubin) in zebrafish Wilson's disease model.
- Preclinical study published in Advances in Redox Research; demonstrates reductions in oxidative stress, ROS-Ca²⁺ amplification, and tissue degeneration.
- First peer-reviewed publication for Telomir-Zn in Wilson's disease; supports mechanism across copper-redox modulation and mitochondrial protection.
- Telomir-Zn already has FDA IND clearance for Phase 1/2 in Triple-Negative Breast Cancer (April 2026); new data further validates platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226024517/0001493152-26-024517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226024517/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer